Venus Remedies achieves Marketing Authorizations for Docetaxel in Israel and Cytarabine in Colombia

Venus Remedies, a global leader in pharmaceutical innovation, is excited to announce dual achievements in securing marketing authorisations for three variants of Docetaxel in Israel and Cytarabjne 100MG in Colombia. The approved Docetaxel variants (160MG/8ML, 80MG/4ML, 20MG/1ML) and Cytarabine further solidify our commitment to advancing healthcare solutions globally.

Shares of Venus Remedies Limited was last trading in BSE at Rs. 391.80 as compared to the previous close of Rs. 384.00. The total number of shares traded during the day was 23011 in over 1108 trades.

The stock hit an intraday high of Rs. 401.30 and intraday low of 389.00. The net turnover during the day was Rs. 9100029.00.

Source : Equity Bulls

Keywords

VenusRemedies INE411B01019 Authorisation Docetaxel Israel Cytarabine Colombia